Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to Lineage	$ (5,760,000)	$ (5,229,000)	$ (12,302,000)	$ (9,601,000)
Net loss attributable to noncontrolling interest	(13,000)	26,000	(29,000)	(6,000)
Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc.to net cash used in operating activities:
Loss on marketable equity securities, net	10,000	150,000	15,000	110,000
Accretion of income on marketable debt securities			(102,000)	(516,000)
Depreciation and amortization expense	142,000	138,000	295,000	276,000
Change in right-of-use assets and liabilities			(20,000)	81,000
Amortization of intangible assets	0	32,000	22,000	65,000
Stock-based compensation			2,432,000	2,311,000
Deferred income tax benefit			0	(1,803,000)
Foreign currency remeasurement and other loss			767,000	1,011,000
Changes in operating assets and liabilities:
Accounts receivable			508,000	(147,000)
Prepaid expenses and other current assets			516,000	(270,000)
Accounts payable and accrued liabilities			(1,245,000)	(3,941,000)
Deferred revenue			(1,816,000)	(5,080,000)
Net cash used in operating activities			(10,959,000)	(17,510,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of marketable equity securities			18,000	0
Purchases of marketable debt securities			(8,761,000)	(12,635,000)
Maturities of marketable debt securities			0	47,664,000
Purchase of equipment			(88,000)	(444,000)
Net cash (used in) provided by investing activities			(8,831,000)	34,585,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from employee options exercised			219,000	80,000
Common shares received and retired for employee taxes paid			(23,000)	(37,000)
Proceeds from sale of common shares			14,070,000	5,789,000
Payments for offering costs			(113,000)	(174,000)
Repayment of finance lease liabilities			(27,000)	(29,000)
Net cash provided by financing activities			14,126,000	5,629,000
Effect of exchange rate changes on cash, cash equivalents and restricted cash			(158,000)	(192,000)
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH			(5,822,000)	22,512,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
At beginning of the period			35,992,000	11,936,000
At end of the period	30,170,000	34,448,000	30,170,000	34,448,000
SUPPLEMENTAL DISCLOSURES :
Cash paid for interest			4,000	5,000
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTINGACTIVITIES:
Property and equipment expenditures in accounts payable			58,000	93,000
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Cash and cash equivalents	29,622,000	33,886,000	29,622,000	33,886,000
Restricted cash included in deposits and other long-term assets (see Note 13 (Commitments and Contingencies))	548,000	562,000	548,000	562,000
Total cash, cash equivalents, and restricted cash	$ 30,170,000	$ 34,448,000	$ 30,170,000	$ 34,448,000